ABBV241101P125000
- 0.00
- 0.000.00%
AbbVie Newsroom
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday
Nasdaq Hits Record High While Wed Earnings Are Mixed | Wall Street Today
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion, Expanding Alzheimer's Pipeline
AbbVie Small Cell Lung Cancer Treatment (An Antibody Drug Conjugate Comprising Monoclonal Antibody Anti-SEZ6 IgG1 Antibody Conjugated To A Top1 Inhibitor) Granted FDA Orphan Designation
AbbVie Q3 Earnings Preview: Modest Guidance Raise Expected
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
Tuesday Market Falls on Tough Earnings, With AMD and Alphabet Reporting Tonight | Live Stock
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie's VRAYLAR Now Publicly Reimbursed In Ontario On Its Provincial Formulary As A General Benefit; Listing Will Be Effective On October 31, 2024
Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?
Express News | Abbvie's Vraylar® (Cariprazine) Now Publicly Reimbursed in Ontario
AbbVie Signs Agreement to Acquire Aliada for $1.4bn
SkinSpirit Joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
Health Care Up Amid Deal Activity -- Health Care Roundup
News Highlights: Top Company News of the Day - Monday at 5 PM ET
Slow Day to Start Busy Week | Wall Street Today
Sector Update: Health Care Stocks Edge Up Monday Afternoon
Sector Update: Health Care
Market Climbs as Investors Prepare for Biggest Earnings Week of the Year | Live Stock
Top Midday Stories: Boeing Launches Public Offerings; McDonald's Quarter Pounder to Return to Menus This Week